Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
Status:
Enrolling by invitation
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE
combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment
will continue until disease progression or intolerable toxicity or patients withdrawal of
consent,and the target sample size is 60 individuals.